Management of irritable bowel syndrome

Gunn, M; Cavin, Anne-Laure; Mansfield, J C

doi:10.1136/pmj.79.929.154

Cited by 18 publications

(12 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15 IBS accounts for up to 50% of consultations with gastroenterologists. 16 Patients with a formal diagnosis of IBS have been reported to have an increased number of consultations per year, both in primary and secondary care, as compared with patients without this diagnosis (8.6-9.0 versus 4.6). 17 Up to 85% of IBS patients undergo an investigation, with the most frequent being an abdominal ultrasound (approximately half) and a colonoscopy (approximately one-third).…”

Section: The Burden Of Ibs On Healthcare Systemsmentioning

confidence: 99%

The global impact of IBS: time to think about IBS-specific models of care?

Corsetti

Whorwell

2017

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal (GI) disorder that can significantly erode the quality of life (QoL) of sufferers and places a major cost burden on healthcare services. This paper reviews the literature on the impact of IBS on healthcare services and society, including a recent report on the subject, in order to formulate a plan for the future. A completely different model of care for these patients is recommended based on this review and the experience of the two authors who have been treating patients with functional GI disorders for 20 and 35 years, respectively.

show abstract

Section: The Burden Of Ibs On Healthcare Systemsmentioning

confidence: 99%

The global impact of IBS: time to think about IBS-specific models of care?

Corsetti

Whorwell

2017

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Les croyances mystiques seraient plus fré-quemment exprimées par le patient souffrant de SII comparé au patient souffrant de CC en Côte-d'Ivoire. Ce constat permettrait, s'il était confirmé par d'autres études, de distinguer dans une approche pragmatique basée sur les symptômes, le patient souffrant de SII, lorsque celui-ci exprimerait des croyances mystiques pendant la consultation, de celui souffrant uniquement de CC et d'en tenir compte dans sa prise en charge [25,26].…”

Section: Resultsunclassified

Croyances mystiques et syndrome de l’intestin irritable chez le patient noir africain

N’Dri-Yoman¹,

Mahassadi²,

Touré³

et al. 2010

J Afr Hepato Gastroenterol

View full text Add to dashboard Cite

Contexte : Le patient africain souffrant de syndrome de l'intestin irritable (SII) aurait tendance à exprimer plus de croyances mystiques (sorcellerie, envoûtement, mauvais sort) que le patient souffrant de constipation chronique (CC). But : Comparer les facteurs cliniques et sociologiques associés au SII et à la CC. Patients et méthodes : Une étude transversale a été conduite au centre hospitalier et universitaire (CHU) de Yopougon et a inclus 78 patients noirs africains sachant lire et écrire (51 femmes et 27 hommes, âge médian : 32,7 ans) vus pour douleur abdominale ou trouble du transit (constipation ou diarrhée). Chaque patient remplissait un autoquestionnaire comprenant les items sur les critères de Rome 2 du SII et de la CC, sur les caractéristiques démographiques et sociologiques (antécédents de sorcellerie, envoûtement, conflit avec l'entourage ou de deuil). Résultats : Au total, 11 patients (13,4 %) souffraient de SII et 67 (81,7 %) de CC. Les patients souffrant de SII étaient en majorité des hommes (72,7 vs 28,4 % ; p = 0,01), avec une durée d'évolution plus longue des symptômes (5 vs 1 an, p = 0,02), et exprimaient plus les croyances mystiques (36,4 vs 6,8 % ; p = 0,02) comparés aux patients souffrant de CC en analyse univariée. En analyse multivariée, les hommes : (OR = 4,7 ; IC 95 % : [1,1-21,1] ; p = 0,04) et les croyances mystiques (OR = 5,9 ; IC 95 % : [1,1-32,1] ; p = 0,04) étaient associés au SII. Conclusion : Les croyances mystiques étaient associées au SII. La présence de celles-ci permettrait d'identifier les patients souffrant de SII, lorsque ceux-ci ont des symptômes en faveur du SII. Mots clés Syndrome de l'intestin irritable · Constipation chronique · Croyances mystiques · Afrique noireAbstract Background: Black African patients with irritable bowel syndrome (IBS) were prompt to express mystic beliefs than patients with chronic constipation (CC) regarding their illness. Aim: To compare clinical and sociological factors of IBS and CC. Patients and methods: Cross-sectional study was conducted at Yopougon teaching hospital from April 2004 to January 2005 and enrolled 78 consecutive outpatients (51 females, 27 males, median age: 32.7 years) attending the gastroenterology unit for functional gastrointestinal disorders (IBS and CC). Each patient completed a questionnaire including Rome II criteria of IBS and CC, demographic and sociological parameters (past history of sorcery, bewitchment, intra familial conflict). Results: Among these patients, 11 (13.4%) had IBS and 67 (81.7%) had CC. Patients with IBS were mainly males (72.7 vs 28.4%, P = 0.01), had long duration (in years) of symptoms (5 vs 1 year, P = 0.02) and expressed mystic belief (36.4 vs 6%, P = 0.02)than patients with CC in univariate analysis. In multivariate logistic regression analysis, males (OR = 4.7; CI 95%: [1.1-21.1]; P = 0.04) and mystic belief (OR = 5.9; CI 95 %: [1.1-32.1]; P = 0.04) were significantly associated with IBS. Conclusion: Black African patients with IBS were mainly males and expressed mystic belief than thos...

show abstract

“…In the UK,~17% of the general population live with IBS, and up to 50% of all general practitioner (GP) visits for gastrointestinal disturbances relate to IBS symptoms [19]. IBS poses a significant personal, societal and economic burden [20][21][22], thus clinically effective and pragmatic treatment options which serve to reduce the symptoms of IBS are much needed. Although several reviews have previously concluded that probiotics improve IBS symptoms including abdominal pain [23][24][25][26][27][28], many reviews feature studies investigating the use of composite probiotic mixtures containing several strains of Lactobacillus, Bifidobacterium and Propionibacterium, which hampers the assessment of specific strains in relieving IBS symptoms.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Bifidobacterium on Reducing Symptomatic Abdominal Pain in Patients with Irritable Bowel Syndrome: A Systematic Review

Pratt

Campbell

2019

Probiotics & Antimicro. Prot.

View full text Add to dashboard Cite

Probiotics, specifically Bifidobacteria, may improve abdominal pain in patients with irritable bowel syndrome (IBS); however, results from randomised controlled trials (RCTs) are conflicting. Here, we systematically reviewed the efficacy of Bifidobacteria on abdominal pain in IBS. We searched MEDLINE, EMBASE and the Cochrane Controlled Trials Register from inception to 20 May 2019, without language or date restrictions. The search strategy comprised of the combination of three concepts: supplementation, abdominal pain, and IBS. Inclusion criteria included double-blind placebo-controlled RCTs featuring Bifidobacteria supplementation in Rome-diagnosed IBS patients. A total of 8 RCTs involving a total of 1045 patients with Rome diagnosed IBS were included. The dose of total Bifidobacteria ranged from 10 6 to > 10 11 cfu (colony-forming unit) and duration of supplementation ranged between 2 and 8 weeks. Bifidobacteria was delivered through either intake of fermented milk products, encapsulation or via a malted milk beverage, with all studies assessing abdominal pain via a visual analogue Likert scale. From the studies included, 50% (n = 4) of studies found a statistically significant improvement in abdominal pain following Bifidobacteria supplementation compared to placebo, 38% (n = 3) of studies found non-significant improvements and 12% (n = 1) showed a statistically significant dose-response effect of improvement. The evidence shows a heterogeneity of effect for Bifidobacteria dependent upon strain, dosage and delivery method. While not all studies demonstrate significant improvements in abdominal pain, none of the selected studies reported an increase in pain or other adverse effects.

show abstract

Management of irritable bowel syndrome

Cited by 18 publications

References 53 publications

The global impact of IBS: time to think about IBS-specific models of care?

The global impact of IBS: time to think about IBS-specific models of care?

Croyances mystiques et syndrome de l’intestin irritable chez le patient noir africain

The Effect of Bifidobacterium on Reducing Symptomatic Abdominal Pain in Patients with Irritable Bowel Syndrome: A Systematic Review

Contact Info

Product

Resources

About